{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:38:05Z","timestamp":1784734685863,"version":"3.55.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.neuropharm.2020.108128","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T21:39:45Z","timestamp":1588887585000},"page":"108128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Cebranopadol reduces cocaine self-administration in male rats: Dose, treatment and safety consideration"],"prefix":"10.1016","volume":"172","author":[{"given":"Huimei","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Guo","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.108128_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/bs.vh.2014.10.006","article-title":"Nociceptin\/orphanin-FQ modulation of learning and memory","volume":"97","author":"Abdel-Mouttalib","year":"2015","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.neuropharm.2020.108128_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1124\/jpet.109.152462","article-title":"Increased locomotor activity induced by heroin in mice: pharmacokinetic demonstration of heroin acting as a prodrug for the mediator 6-monoacetylmorphine in vivo","volume":"331","author":"Andersen","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108128_bib3","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/j.bja.2019.03.006","article-title":"Hot topics in opioid pharmacology: mixed and biased opioids","volume":"122","author":"Azzam","year":"2019","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2020.108128_bib4","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1038\/nature16032","article-title":"Global research challenges and opportunities for mental health and substance-use disorders","volume":"527","author":"Baingana","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2020.108128_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.npep.2015.03.005","article-title":"Role of nociceptin\/orphanin FQ in thermoregulation","volume":"50","author":"Baiula","year":"2015","journal-title":"Neuropeptides"},{"key":"10.1016\/j.neuropharm.2020.108128_bib6","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/0024-3205(93)90581-M","article-title":"Opiates, mast cells and histamine release","volume":"53","author":"Barke","year":"1993","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2020.108128_bib7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neuropharm.2004.07.007","article-title":"Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats","volume":"47","author":"Barrett","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108128_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4140\/TCP.n.2015.221","article-title":"Opioid-induced pruritus","volume":"30","author":"Benson","year":"2015","journal-title":"Consult. Pharm."},{"key":"10.1016\/j.neuropharm.2020.108128_bib9","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physician"},{"key":"10.1016\/j.neuropharm.2020.108128_bib10","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/j.1476-5381.2011.01300.x","article-title":"Predictive validity of behavioural animal models for chronic pain","volume":"164","author":"Berge","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108128_bib11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/SPC.0000000000000129","article-title":"Simultaneous targeting of multiple opioid receptor types","volume":"9","author":"Bird","year":"2015","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.neuropharm.2020.108128_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1369-1600.2010.00298.x","article-title":"Pharmacokinetic modeling of subcutaneous heroin and its metabolites in blood and brain of mice","volume":"18","author":"Boix","year":"2013","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2020.108128_bib13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-3565(25)23126-3","article-title":"Behavioral and neurochemical interactions between cocaine and buprenorphine: implications for the pharmacotherapy of cocaine abuse","volume":"256","author":"Brown","year":"1991","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108128_bib14","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3122\/jabfm.2018.05.180045","article-title":"If we don't ask, they won't tell: screening for urinary and fecal incontinence by primary care providers","volume":"31","author":"Brown","year":"2018","journal-title":"J. Am. Board Fam. Med."},{"key":"10.1016\/j.neuropharm.2020.108128_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0006-8993(90)91083-S","article-title":"Participation of different brain regions in the anti-narcotic withdrawal action of clonidine in the dependent rat","volume":"513","author":"Buccafusco","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108128_bib16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/0014-5793(94)00561-3","article-title":"Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type","volume":"347","author":"Bunzow","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2020.108128_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jsat.2017.10.010","article-title":"Understanding abuse of buprenorphine\/naloxone film versus tablet products using data from ASI-MV(R) substance use disorder treatment centers and RADARS(R) System Poison Centers","volume":"84","author":"Butler","year":"2018","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.neuropharm.2020.108128_bib18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1073\/pnas.1517713113","article-title":"Long-acting cocaine hydrolase for addiction therapy","volume":"113","author":"Chen","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2020.108128_bib19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0014-5793(94)00560-5","article-title":"Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family","volume":"347","author":"Chen","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2020.108128_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/138945007779315605","article-title":"Nociceptin\/orphanin FQ peptide receptors: pharmacology and clinical implications","volume":"8","author":"Chiou","year":"2007","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.neuropharm.2020.108128_bib21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00213-003-1645-1","article-title":"Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin\/orphanin FQ in alcohol-preferring rats","volume":"172","author":"Ciccocioppo","year":"2004","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2020.108128_bib22","doi-asserted-by":"crossref","first-page":"1092\u20101103","DOI":"10.1038\/npp.2011.226","article-title":"Long\u2010lasting effects of a PEGylated mutant cocaine esterase (CocE) on the reinforcing and discriminative stimulus effects of cocaine in rats","volume":"37","author":"Collins","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108128_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1300\/J069v14n03_07","article-title":"Buprenorphine as a pharmacotherapy for cocaine abuse: a review of the evidence","volume":"14","author":"Compton","year":"1995","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.neuropharm.2020.108128_bib24","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMra1508490","article-title":"Relationship between nonmedical prescription-opioid use and heroin use","volume":"374","author":"Compton","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2020.108128_bib25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1124\/jpet.117.241042","article-title":"Cebranopadol blocks the escalation of cocaine intake and conditioned reinstatement of cocaine seeking in rats","volume":"362","author":"de Guglielmo","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108128_bib26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/bja\/aep129","article-title":"Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile","volume":"103","author":"Dietis","year":"2009","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2020.108128_bib27","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/MLR.0000000000000625","article-title":"The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013","volume":"54","author":"Florence","year":"2016","journal-title":"Med. Care"},{"key":"10.1016\/j.neuropharm.2020.108128_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0014-5793(94)80603-9","article-title":"cDNA cloning and regional distribution of a novel member of the opioid receptor family","volume":"343","author":"Fukuda","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2020.108128_bib29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JCP.0000000000000995","article-title":"Assessment of the abuse potential of cebranopadol in nondependent recreational opioid users: a phase 1 randomized controlled study","volume":"39","author":"Gohler","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108128_bib30","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.pbb.2007.01.020","article-title":"Chronic buprenorphine reduces the response to sucrose-associated cues in non food-deprived rats","volume":"86","author":"Hood","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2020.108128_bib31","doi-asserted-by":"crossref","first-page":"14854","DOI":"10.1073\/pnas.94.26.14854","article-title":"Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress","volume":"94","author":"Jenck","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108128_bib32","first-page":"719","article-title":"Vital signs: demographic and substance use trends among heroin users - United States, 2002-2013","volume":"64","author":"Jones","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.neuropharm.2020.108128_bib33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1176\/ajp.2007.164.5.797","article-title":"A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial","volume":"164","author":"Kakko","year":"2007","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108128_bib34","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.2174\/092986712803988839","article-title":"Diagnosis and consequences of cocaine addiction","volume":"19","author":"Karila","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108128_bib35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41398-017-0080-8","article-title":"A systematic review of the role of the nociceptin receptor system in stress, cognition, and reward: relevance to schizophrenia","volume":"8","author":"Khan","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2020.108128_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cbi.2018.08.002","article-title":"Kinetic characterization of cholinesterases and a therapeutically valuable cocaine hydrolase for their catalytic activities against heroin and its metabolite 6-monoacetylmorphine","volume":"293","author":"Kim","year":"2018","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.neuropharm.2020.108128_bib37","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0022-3565(24)36842-9","article-title":"Mu opioid agonists potentiate amphetamine- and cocaine-induced rotational behavior in the rat","volume":"282","author":"Kimmel","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108128_bib38","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jpainsymman.2019.05.012","article-title":"Cebranopadol, a novel first-in-class Analgesic drug candidate: first experience with cancer-related pain for up to 26 weeks","volume":"58","author":"Koch","year":"2019","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.neuropharm.2020.108128_bib39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsat.2014.02.003","article-title":"Abuse and diversion of buprenorphine sublingual tablets and film","volume":"47","author":"Lavonas","year":"2014","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.neuropharm.2020.108128_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/FBP.0b013e3282f3cf84","article-title":"Topiramate does not alter nicotine or cocaine discrimination in rats","volume":"19","author":"Le Foll","year":"2008","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108128_bib41","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1124\/jpet.114.213694","article-title":"Cebranopadol: a novel potent analgesic nociceptin\/orphanin FQ peptide and opioid receptor agonist","volume":"349","author":"Linz","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108128_bib42","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1126\/science.1084674","article-title":"5-HT4(a) receptors avert opioid-induced breathing depression without loss of analgesia","volume":"301","author":"Manzke","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2020.108128_bib43","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0014-5793(94)80235-1","article-title":"ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization","volume":"341","author":"Mollereau","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2020.108128_bib44","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/jpet.110.169979","article-title":"How good are current approaches to nonclinical evaluation of abuse and dependence?","volume":"336","author":"Moser","year":"2011","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108128_bib45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.neuropharm.2020.108128_bib46","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1021\/acschemneuro.9b00305","article-title":"6-Monoacetylmorphine (6-MAM), not morphine, is responsible for the rapid neural effects induced by intravenous heroin","volume":"10","author":"Perekopskiy","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108128_bib47","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1039\/C3OB42464B","article-title":"Reaction pathways and free energy profiles for cholinesterase-catalyzed hydrolysis of 6-monoacetylmorphine","volume":"12","author":"Qiao","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.neuropharm.2020.108128_bib48","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.1021\/bi400709v","article-title":"Fundamental reaction pathway and free energy profile for butyrylcholinesterase-catalyzed hydrolysis of heroin","volume":"52","author":"Qiao","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2020.108128_bib49","series-title":"Animal Models of Drug Addiction","first-page":"233","article-title":"Self-administration of psychomotor stimulants using progressive ratio schedules of reinforcement","author":"Roberts","year":"1992"},{"key":"10.1016\/j.neuropharm.2020.108128_bib50","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/sj.clpt.6100164","article-title":"Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone","volume":"82","author":"Rosow","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2020.108128_bib51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.peptides.2018.12.001","article-title":"NOP agonist action of cebranopadol counteracts its liability to promote physical dependence","volume":"112","author":"Ruzza","year":"2019","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2020.108128_bib52","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.npp.1301459","article-title":"Endogenous nociceptin (orphanin FQ) suppresses basal hedonic state and acute reward responses to methamphetamine and ethanol, but facilitates chronic responses","volume":"33","author":"Sakoori","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108128_bib53","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fpsyt.2017.00234","article-title":"Cebranopadol, a mixed opioid agonist, reduces cocaine self-administration through nociceptin opioid and mu opioid receptors","volume":"8","author":"Shen","year":"2017","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108128_bib54","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2174\/13894501113149990174","article-title":"Nociceptin\/orphanin FQ (NOP) receptors as novel potential target in the treatment of gastrointestinal diseases","volume":"14","author":"Sobczak","year":"2013","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.neuropharm.2020.108128_bib55","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/sj.npp.1300712","article-title":"Rats maintained chronically on buprenorphine show reduced heroin and cocaine seeking in tests of extinction and drug-induced reinstatement","volume":"30","author":"Sorge","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108128_bib56","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejphar.2013.01.076","article-title":"Opioids, sensory systems and chronic pain","volume":"716","author":"Stein","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108128_bib57","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1385-299X(02)00185-X","article-title":"Jugular vein catheterization for repeated blood sampling in the unrestrained conscious rat","volume":"10","author":"Thrivikraman","year":"2002","journal-title":"Brain Res. Brain Res. Protoc."},{"key":"10.1016\/j.neuropharm.2020.108128_bib58","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3181\/00379727-60-15143","article-title":"The porphyrin of Harder's gland","volume":"60","author":"Towbin","year":"1945","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.neuropharm.2020.108128_bib59","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/adb.12550","article-title":"Limited potential of cebranopadol to produce opioid-type physical dependence in rodents","volume":"23","author":"Tzschentke","year":"2018","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2020.108128_bib60","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/164_2019_206","article-title":"Cebranopadol: a novel first-in-class potent analgesic acting via NOP and opioid receptors","volume":"254","author":"Tzschentke","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108128_bib61","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.neuropharm.2017.11.026","article-title":"Mu-opioid peptide (MOP) and nociceptin\/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat","volume":"129","author":"Tzschentke","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108128_bib62","series-title":"World Drug Report from the United Nations Office on Drugs and Crime","author":"UNODC","year":"2018"},{"key":"10.1016\/j.neuropharm.2020.108128_bib63","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.neuropharm.2008.01.001","article-title":"Predictive validity of animal pain models? A comparison of the pharmacokinetic-pharmacodynamic relationship for pain drugs in rats and humans","volume":"54","author":"Whiteside","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108128_bib64","doi-asserted-by":"crossref","first-page":"126754","DOI":"10.1016\/j.bmcl.2019.126754","article-title":"Discovery of potent and selective butyrylcholinesterase inhibitors through the use of pharmacophore-based screening","volume":"29","author":"Williams","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.neuropharm.2020.108128_bib65","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.pharmthera.2013.10.011","article-title":"The biology of Nociceptin\/Orphanin FQ (N\/OFQ) related to obesity, stress, anxiety, mood, and drug dependence","volume":"141","author":"Witkin","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2020.108128_bib66","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0301-0082(98)00067-7","article-title":"Nociceptin\/orphanin FQ: role in nociceptive information processing","volume":"57","author":"Yamamoto","year":"1999","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2020.108128_bib67","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/jpmn.2001.25012","article-title":"Definition of and mechanism for opioid-induced sedation","volume":"2","author":"Young-McCaughan","year":"2001","journal-title":"Pain Manag. Nurs."},{"key":"10.1016\/j.neuropharm.2020.108128_bib68","doi-asserted-by":"crossref","first-page":"16762","DOI":"10.1038\/s41598-018-35196-8","article-title":"Blocking drug activation as a therapeutic strategy to attenuate acute toxicity and physiological effects of heroin","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2020.108128_bib69","doi-asserted-by":"crossref","first-page":"15303","DOI":"10.1038\/s41598-017-14105-5","article-title":"Clinical potential of an enzyme-based novel therapy for cocaine overdose","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2020.108128_bib70","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1097\/00001756-200312190-00019","article-title":"Orphanin FQ\/nociceptin blocks methamphetamine place preference in rats","volume":"14","author":"Zhao","year":"2003","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2020.108128_bib71","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10822-007-9144-9","article-title":"Rational design of an enzyme mutant for anti-cocaine therapeutics","volume":"22","author":"Zheng","year":"2008","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.neuropharm.2020.108128_bib72","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4155\/fmc.09.20","article-title":"Recent progress in protein drug design and discovery with a focus on novel approaches to the development of anti-cocaine medications","volume":"1","author":"Zheng","year":"2009","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108128_bib73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4155\/fmc.10.275","article-title":"Enzyme therapy approaches for treatment of drug overdose and addiction","volume":"3","author":"Zheng","year":"2011","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108128_bib74","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4155\/fmc.11.171","article-title":"Are pharmacokinetic approaches feasible for treatment of cocaine addiction and overdose?","volume":"4","author":"Zheng","year":"2012","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108128_bib75","series-title":"Biologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzymes","first-page":"187","article-title":"Cocaine hydrolases designed from butyrylcholinesterase","author":"Zheng","year":"2016"},{"key":"10.1016\/j.neuropharm.2020.108128_bib76","series-title":"The Neuroscience of Cocaine: Mechanisms and Treatment","first-page":"663","article-title":"Actions of butyrylcholinesterase against cocaine","author":"Zheng","year":"2017"},{"key":"10.1016\/j.neuropharm.2020.108128_bib77","doi-asserted-by":"crossref","first-page":"107462","DOI":"10.1016\/j.drugalcdep.2019.04.033","article-title":"In vivo characterization of toxicity of norcocaethylene and norcocaine identified as the most toxic cocaine metabolites in male mice","volume":"204","author":"Zheng","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2020.108128_bib78","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.cbi.2019.05.051","article-title":"Structure-based virtual screening leading to discovery of highly selective butyrylcholinesterase inhibitors with solanaceous alkaloid scaffolds","volume":"308","author":"Zhou","year":"2019","journal-title":"Chem. Biol. Interact."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820301969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820301969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:00:37Z","timestamp":1758438037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820301969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":78,"alternative-id":["S0028390820301969"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108128","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cebranopadol reduces cocaine self-administration in male rats: Dose, treatment and safety consideration","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108128"}}